Scientists discovered that a protein called RNF128 plays a major role in causing fatty liver disease, a condition where fat builds up in the liver. When they removed this protein in mice, the disease improved significantly. The research shows that RNF128 works by protecting another protein called SCD1, which helps create fat in liver cells. This discovery could lead to new treatments that block RNF128, potentially helping millions of people with fatty liver disease. The findings were tested in mice and human tissue samples, showing promising results for future medical treatments.
The Quick Take
- What they studied: How a protein called RNF128 causes fatty liver disease to get worse, and whether blocking it could be a treatment
- Who participated: Laboratory mice fed a high-fat diet to develop fatty liver disease, plus human liver tissue samples from people with the disease
- Key finding: Removing RNF128 from liver cells significantly reduced fat buildup and disease severity in mice, while adding more RNF128 made the disease worse
- What it means for you: This research suggests that new drugs targeting RNF128 could potentially treat fatty liver disease, though human testing is still needed before any treatment becomes available
The Research Details
Researchers used multiple approaches to understand RNF128’s role in fatty liver disease. First, they analyzed gene activity in liver tissue from people with the disease and compared it to healthy livers. They then created mice with fatty liver disease by feeding them a high-fat, high-cholesterol diet. To test whether RNF128 causes the disease, they created special mice where this protein was removed only from liver cells. They also created mice with extra RNF128 to see if more of the protein made disease worse. Finally, they tested potential treatments by blocking RNF128 using two different methods: a special molecule called an antisense oligonucleotide and a genetic therapy approach.
This research approach is important because it moves from observation (finding RNF128 is high in sick livers) to cause-and-effect testing (removing it improves disease). By testing both removal and overexpression of the protein, researchers could confirm RNF128 actually causes the problem rather than just being present during disease. Testing potential treatments in mice before human trials is a standard and necessary step in drug development.
The study used multiple complementary techniques including gene sequencing, protein analysis, and animal models to confirm findings. The research was published in Hepatology, a top-tier medical journal focused on liver disease. The use of both genetic deletion and overexpression experiments strengthens confidence in the results. However, as with all animal studies, results in mice may not perfectly translate to humans, and human clinical trials would be needed to confirm effectiveness in people.
What the Results Show
The researchers found that RNF128 protein is present at higher levels in livers of people with fatty liver disease compared to healthy people. In mice fed a high-fat diet, RNF128 levels also increased significantly. When scientists removed the RNF128 gene specifically from liver cells in mice, the fatty liver disease improved dramatically—the mice had less fat buildup and less inflammation in their livers. Conversely, when they increased RNF128 levels in mice, the disease got worse with more fat accumulation. These results clearly showed that RNF128 drives the disease forward. The researchers then identified exactly how RNF128 works: it protects another protein called SCD1 from being broken down by the cell’s natural cleanup system. SCD1 is an enzyme that helps create fat molecules, so when RNF128 keeps it around longer, more fat gets made in liver cells.
Additional experiments confirmed that blocking SCD1 could reverse the harmful effects of RNF128, even when RNF128 was overexpressed. This finding is important because it shows that RNF128’s main harmful effect works through SCD1. The researchers also tested two different therapeutic approaches to block RNF128: one using a modified molecule that targets RNF128 and another using gene therapy. Both approaches successfully reduced fatty liver disease in mice, suggesting multiple possible treatment strategies could work.
Previous research had identified that SCD1 is important in fatty liver disease, but this study reveals a new mechanism—that RNF128 controls SCD1 levels. This fills a gap in understanding how SCD1 is regulated in fatty liver disease. The research also adds to growing evidence that E3 ubiquitin ligases (a class of proteins that tag other proteins for destruction) play central roles in metabolic diseases. This study is among the first to identify RNF128 specifically as a major driver of fatty liver disease.
The study was conducted primarily in mice, and mouse models don’t perfectly replicate human disease. The research used laboratory-created conditions (high-fat diet) that may not exactly match how fatty liver disease develops in real people. The potential treatments were only tested in mice, not in humans, so safety and effectiveness in people remain unknown. The study focused on one specific mechanism (the RNF128-SCD1 axis), but fatty liver disease is complex and involves many other factors not fully explored here. Additionally, the sample size of human tissue samples analyzed was not specified in the abstract.
The Bottom Line
Based on this research, blocking RNF128 appears promising as a potential treatment strategy for fatty liver disease (moderate confidence level). However, these findings are preliminary and based on animal studies. Current recommendations for managing fatty liver disease remain: maintain a healthy weight, eat a balanced diet low in processed foods and added sugars, exercise regularly, and limit alcohol. Anyone with fatty liver disease should work with their doctor on proven treatments while researchers continue developing new options.
This research is most relevant to people with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease. It’s also important for people at risk of developing fatty liver disease, including those who are overweight, have type 2 diabetes, or have metabolic syndrome. Researchers and pharmaceutical companies developing new treatments should pay close attention. People without liver disease don’t need to take action based on this research yet, as treatments are still in development.
This research is in early stages. If development proceeds smoothly, it typically takes 5-10 years to move from laboratory findings to human clinical trials, and several more years for regulatory approval. People should not expect RNF128-blocking treatments to be available immediately, but this research represents an important step toward new therapeutic options for fatty liver disease.
Want to Apply This Research?
- Users with fatty liver disease or at-risk factors should track weekly: weight (same time, same scale), waist circumference, and liver enzyme levels from blood tests (ALT and AST). This creates a baseline to monitor if future RNF128-targeting treatments become available and to assess response to current lifestyle interventions.
- Start tracking dietary fat intake (especially saturated fats and processed foods) and daily physical activity minutes. Set a goal to reduce added sugar consumption and increase exercise to 150 minutes weekly. These evidence-based changes help manage fatty liver disease while researchers develop new treatments like RNF128 inhibitors.
- Establish a quarterly check-in system: track weight trends, update food and exercise logs, and schedule regular liver function blood tests with your doctor. Once RNF128-targeting treatments become available, this historical data will help measure treatment effectiveness. Share trends with your healthcare provider to adjust lifestyle interventions as needed.
This research describes laboratory and animal studies of a potential new treatment target for fatty liver disease. These findings have not yet been tested in humans. This article is for educational purposes only and should not be considered medical advice. Anyone with fatty liver disease or concerns about liver health should consult with their healthcare provider about proven treatment options. Do not stop or change any current treatments based on this research. Future human clinical trials will be necessary to determine if RNF128-blocking treatments are safe and effective in people.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.